Efficacy of Adiuvant Therapy with Procarbazine, MCNU, and Vincristine for Oligodendroglial Tumors.

Wakabayashi, Toshihiko; Kajita, Yasukazu; Mizuno, Masaaki; Nagasaka, Tetsuo; Yoshida, Jun

doi:10.2176/nmc.41.115

Cited by 3 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interferon-beta has been used in Japan as an adjuvant therapy for some patients with malignant glioma [15]. It has a direct tumor-suppressive effect [16], and also acts as an immunomodulator [12] and anti-angiogenetic agent [17,18].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma

et al. 2007

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma

et al. 2007

View full text Add to dashboard Cite

show abstract

“…7 In a study involving Japanese patients with oligodendroglial tumors, patients received a lower dose (80 mg/m 2 ) of MCNU (ranimustine) because of frequent dose reductions and dose delays experienced with the "standard" dose (110 to 130 mg/m 2 ). 8 Another Japanese study cycled ACNU (nimustine) every 8 weeks at a decreased dose (75 to 80 mg/m 2 ) 9 because of severe hematologic toxicity after a standard dose of 100 mg/m 2 . 10 Our study results are consistent with views that the optimal PCV chemotherapy dose for Asian patients is lower than that proposed by current regimens from Western countries.…”

mentioning

confidence: 99%

Paroxysmal vertigo as the presenting symptom of Fabry disease

Prüß

Böhner²,

Zschenderlein³

2006

Neurology

View full text Add to dashboard Cite

Abstract-The authors propose "decreased-dose-intensity" PCV (procarbazine, lomustine [CCNU], and vincristine) chemotherapy for Asian patients with oligodendroglial tumors. In this study, all seven patients with oligodendroglioma (OD) and eight with anaplastic oligodendroglioma (AO) had objective responses or stable disease. Median progression-free survival was greater than 29 months (OD) and 36.5 months or greater (AO); 86% of patients with OD and 63% with AO remain progression-free. Twenty-four Common Toxicity Criteria Grade 3/4 adverse events were noted. NEUROLOGY 2006;66:247-249 A.U. Ty, MD; S.J. See, MD; J.P. Rao, MD; J.B.K. Khoo, MD, FRCR; and M.C. Wong, FRCP Oligodendroglial tumors are among the most chemosensitive of human solid malignancies. In terms of cost and availability, PCV (procarbazine, lomustine [CCNU], and vincristine) chemotherapy is the most viable chemotherapeutic option for patients with oligodendroglial tumors in Asia. PCV-associated toxicity, particularly cumulative myelosuppression, is well described among white patients.1,2 There are no reports in the published literature describing Asian oligodendroglial PCV chemotherapy outcome. In our experience, most Asian patients cannot tolerate the toxicity associated with the Western "standard" PCV dose. We developed a "decreased-dose-intensity" PCV regimen for our Asian patients, and this study reports our experience. All patients underwent MRI scanning within 14 days before initiation of chemotherapy, after the second or third cycle, at the end of chemotherapy, when clinical progression was suspected, and at least 6 monthly follow-up intervals. Tumor size was measured via the product of the two largest perpendicular diameters. Metastasis along the ventricular lining or cortical surface was considered evidence of leptomeningeal disease (LMD). Postgadolinium T1-weighted images were used to measure enhancing tumors, and T2-weighted or fluid-attenuated inversion recovery images were used for non-contrast-enhancing tumors.Conventional measures of response such as complete response (CR), partial response (PR), stable disease, and progressive disease (PD) were used. 3 The proportion of [CR ϩ PR] constituted the objective response rate. Progression-free survival (PFS) was the period from initiation of chemotherapy to disease progression or death. Grade 3/4 Common Toxicity Criteria (NCI-CTC version 2.0) adverse events (AEs) were noted.Results. Treatment outcome and PFS data are summarized in table 1. No patient had development of PD while undergoing chemotherapy. Five patients with OD were given up-front PCV because they all had clinically symptomatic, radiologically extensive, surgically unresectable, and thus "aggressive" low-grade ODs. We observed early (after 2 or 3 cycles of PCV) objective responses in 57% of patients with OD and 13% of patients with AO. Among patients with OD, median PFS was greater than 29 months (range of Ͼ 23 to Ͼ 40 months). Six of seven patients (86%) remain progression free, whereas one patient (13%) had development of d...

show abstract

Treatment Recommendations for Adult Patients with Diffuse Gliomas of Grades II and III According to the New WHO Classification in 2016

Sasaki

Yoshida

2017

Neurol. Med. Chir.(Tokyo)

View full text Add to dashboard Cite

With advanced understanding of molecular background and correlation with therapeutic outcomes, the revised 4th edition of World Health Organization (WHO) classification of central nervous system (CNS) tumors incorporated molecular information into the definition of diffuse gliomas. Indeed, oligodendroglioma and astrocytoma are now defined by molecular signature, with diagnosis of glioblastoma being made by histology. In parallel, numerous clinical trials are underway all over the world, and important findings are being produced every year that have an impact on patient outcomes. Moreover, novel therapies/technologies are also being actively developed; however, there are still many CNS tumors for which no effective therapy has been established except radiotherapy. In this article, the authors review the recent results of major clinical trials and present their treatment recommendations for patients with adult, supratentorial diffuse gliomas of grades II and III stratified according to the new WHO classification.

show abstract

Efficacy of Adiuvant Therapy with Procarbazine, MCNU, and Vincristine for Oligodendroglial Tumors.

Cited by 3 publications

References 15 publications

Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma

Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma

Paroxysmal vertigo as the presenting symptom of Fabry disease

Treatment Recommendations for Adult Patients with Diffuse Gliomas of Grades II and III According to the New WHO Classification in 2016

Contact Info

Product

Resources

About